The Pharma Letter1h
FDA approves Ozempic for patients with diabetes and CKD
In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Copenhagen Post6h
Danish government announces significant increase in defense spending
Denmark needs to be closer to spending 5 percent of GDP on defense than 2 percent.This was announced by Prime Minister Mette Frederiksen after she concluded her blitz through Europe on Tuesday with a ...
LVMH reports muted sales amid hope that the luxury downturn might finally be ending
I’m not going to report record revenue, but it was nonetheless a robust year," CEO Bernard Arnault said during the earnings ...
Novo’s Ozempic Notches Approval for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression
(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...
The American Journal of Managed Care21h
Breakthrough Drugs Set to Achieve Blockbuster Status by 2030
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
IPWatchdog21h
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...